A Phase 2, Double-Blind, Multiple-Dose Escalation Study to Evaluate NKTR-118 (Oral PEG-Naloxol) in Patients With Opioid-Induced Constipation (OIC)

NCT00600119 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

207

Enrollment

INDUSTRY

Sponsor class

Conditions

Opioid Induced Constipation (OIC)

Interventions

DRUG: placebo
DRUG: NKTR-118

Sponsor

AstraZeneca

Collaborators

[object Object]